Naveen Pemmaraju: Pivekimab sunirine in relapsed or refractory acute myeloid leukaemia

Naveen Pemmaraju shared a post on X about a recent paper by Naval Daver et al. published in The Lancet Oncology.

“Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study”

Authors: Naval Daver, Pau Montesinos, Daniel DeAngelo, Naveen Pemmaraju, Hagop Kantarjian et al.

“Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.”

Source: Naveen Pemmaraju/X

More posts featuring Naveen Pemmaraju on oncodaily.com

Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director.

His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.